Macrophage inflammatory protein 1α attenuates the toxic effects of temozolomide in human bone marrow granulocyte-macrophage colony-forming cells

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 966-970

  Clemons, Mark ^a,c   Watson, Amanda ^a   Howell, Anthony ^a   Chang, James ^b   Heyworth, Claire ^a   Lord, Brian ^a   Testa, Nidya ^a   Dexter, T Michael ^a   Margison, Geoffrey ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MITOZOLOMIDE; STREPTOZOCIN; TEMOZOLOMIDE;

ARTICLE; BLOOD TOXICITY; BONE MARROW CELL; CELL CYCLE G1 PHASE; CELL KILLING; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; GRANULOCYTE; HUMAN; HUMAN CELL; MACROPHAGE; PRIORITY JOURNAL; STEM CELL;

ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW CELLS; CELL DIVISION; CELL SURVIVAL; COLONY-FORMING UNITS ASSAY; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIETIC STEM CELLS; HUMANS; MACROPHAGE INFLAMMATORY PROTEIN-1; STREPTOZOCIN;

EID: 0034017451     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Clemons, M. J., Gharif, R., and Howell, A. Review of dose-intensification of standard chemotherapy for advanced breast cancer using colony-stimulating factors. Cancer Treat. Rev., 24: 173-184, 1998.
2. Lord, B. I., Dexter, T. M., Clements, J. M., Hunter, M A., and Gearing, A. J. Macrophage inflammatory protein protects multipotent haematopoietic cells from the effects of hydroxyurea in vivo. Blood, 79: 2605-2609, 1992.
3. Dunlop, D. J., Wright, E. G , Lorimore, S., Graham, G J., Holyoake, T., Kerr, D. J., Wolpe, S. D., and Pragnell, I. B. Demonstration of stem cell inhibition and myeloprotective effects of SCI/rhMIP1α in vivo. Blood, 79: 2221-2225, 1992.
4. Guigon, M., Enouf, J., and Frindel, E. Effects of CFS-S inhibitors on murine bone marrow during ARA-C treatment, I. Effects on stem cells. Leuk. Res., 4: 385-391, 1980.
5. Paukovits, W. R., Moser, M. H., and Paukovits, J. B. Pre-CFU-S quiescence and stem cell exhaustion after cytostatic drug treatment. Protective effects of the inhibitory peptide pGlu-Glu-Asp-Gys-Lys (pEEDCK). Blood, 87: 1755-1761, 1993.
6. Sonis, S. T., Linquist, L., Van Vugt, A., Stewart, A. A., Stam, K., Qu, G-Y., Iwata, K. K., and Hayley, J. D. Prevention of chemotherapy-induced ulcerarive mucositis by transforming growth factor β3. Cancer Res., 54: 1135-1138, 1994.
7. Wolpe, S. D., and Cerami, A. Macrophage inflammatory proteins 1 and 2: members of a novel superfamily of cytokines. FASEB J., 3: 2565-2573, 1989.
8. Hunter, M. G., Bawden, L., Brotherton, D., Craig, S., Cribbes, S., Czaplewski, L. G., Dexter, T. M., Drummond, A. H., Gearing, A. H., and Heyworth, C. M. BB-10010: an active variant of human macrophage inflammatory protein-1α with improved pharmaceutical properties. Blood, 12: 4400-4408, 1995.
9. Marshall, E., Lord, B. I., and Howell, A. H. Clinical effects of human MIP-1α (LD78) administration to humans: a Phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010. Eur. J. Cancer. 34: 1023-1029, 1997.
10. Clemons, M. J., Marshall, E., Dürig, J., Watanabe, K., Howell, A., Miles, D., Earl, H., Kieman, J., Griffiths, A., Towlson, K., DeTakats, P., Dexter, T. M., Testa, N. G., and Lord, B. I. A randomised Phase 2 study of BB-10010 (macrophage inflammatory protein 1-α) in patients with advanced breast cancer receiving 5-FU, Adriamycin, and cyclophosphamide (FAC) chemotherapy. Blood. 92: 1-11, 1998.
11. Bernstein, S H., Eaves, C. J., Herzig, R., Fay, J., Lynch, J., Phillips, G. L, Christiansen, N., Reece, D., Ericson, S., Stephan, M., Kovalsky, M., Hawkins, K., Rasmussen, H., Devos, A., and Herzig, G. P. A randomized Phase n study of BB-10010: a variant of human macrophage inflammatory protein-1α for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer. Br. J. Haematol., 99: 888-895, 1997.
12. 6-Benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide. Exp. Hematol., 23: 112-116, 1995.
13. 6-Methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br. J. Cancer, 78: 1199-1202, 1998.
14. Coutinho, L. H., Gilleece, M. H, Dewynter, E. A., Will, A., and Testa, N. G. Clonal and long-term culture using human bone marrow. In: N G. Testa and G. M. Molneux (eds.), Haemopoiesis: A Practical Approach, p. 288. Oxford, United Kingdom: IRL Press, 1993.
15. Myers, C. D., Katz, F E., Joshi, G., and Millar, J. L. A cell line secreting stimulating factors for CFU-GEMM culture. Blood, 64: 152-155, 1984.
16. Oppenheim, J. J., Zachanal, C. O. C., Mukaida, N., and Matoushima, R Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu. Rev. Immunol., 9: 617-648, 1991.
17. Cooper, S., Martel, C., and Broxmeyer, H. E. Myelosuppressive effects in vivo with very low dosages of monomeric recombinant murine macrophage inflammatory protein-1α. Exp. Hematol., 22: 186-193, 1994.
18. Broxmeyer, H. E., Sherry, B., and Cooper, S. Macrophage inflammatory protein (MTP) 1β abrogates the capacity of MIP-1α to suppress myeloid progenitor cell growth. J. Immunol., 147: 2978-2983, 1991.
19. Broxmeyer, H. E., Sherry, B., Lu, L., Cooper, S., Oh, K., Tekamp-Olson, P., and Cerami, A. Enhancing and suppressing effects of recombinant murine macrophage inflammatory proteins on colony formation in vitro by bone marrow myeloid progenitor cells. Blood, 76: 1110-1116, 1990.
20. Keller, J. R., Bartelmez, S. H., Sitnicka, R., and Ruscetti, F. W. Distinct and overlapping direct of macrophage inflammatory protein-1α and transforming growth factor β on haematopoietic progenitor/stem cell growth. Blood, 84: 2174-2181, 1994.
21. Lord, B. I., Marshall, E., Woolford, L. B., and Hunter, M. G. BB-10010/MIP-1α in vivo maintains haemopoietic recovery following repeated cycles of sublethal irradiation. Br. J. Cancer, 74: 1017-1022, 1996.
22. Marshall, E., Woolford, L. B., and Lord, B. I. BB-10010 (a variant of human MIP-1α) enhances leucocyte recovery and progenitor cell mobilisation following cyclophosphamide. Br. J. Cancer, 75: 1715-1720, 1997.
23. Cashman, J. D., Eaves, C. J., Sarris, A. H., and Eaves, A. C. MCP-1, not MIP-1α, is the endogenous chemokine that cooperates with TGF-β to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures. Blood, 92: 2338-2344, 1998.
24. Newlands, E. S., Blackledge, G. R. P., Slack, J. A., Stuart, N. S. A., and Stevens, M. F. G. Experimental background and early clinical studies with imidazotetrazine derivatives. In: T. Giraldi, T. A. Connors, and G. A. Cartei (eds.). Triazenes. Chemical. Biological, and Clinical Aspects, p. 184. New York: Plenum Press, 1990.
25. 1-doxyguanosinyl]ethane in DNA treated with N,N′-bis(chloroethyl)-N-nitrosourea. Cancer Res., 42: 3102-3105, 1982.
26. Bodell, W. J., Tokuda, K., and Ludlum, D. B. Differences in DNA alkylation products formed in sensitive and resistant human glioma cells treated with N-(2-chloroethyl)-N-nitrosourea. Cancer Res , 48: 4489-4492, 1988.
27. 6-alkylguanine-DNA alkyltransferase activity potentiates cytotoxicity and induction of SCEs in human glioma cells resistant to 1,3-bis(chloroethyl)-1-nitrosourea. Carcinogenesis (Lond.), 8: 1219-1223, 1987.
28. 6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem. Pharmacol., 46: 285-290, 1993.
29. 6-methylguanine-DNA-methyltransferase. Oncol. Res., 5: 83-86, 1993.
30. Allay, J. A., Dumenco, L. L., Koc, O. N., Liu, L., and Gerson, S. L. Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells. Blood, 85: 3342-3354, 1995.
31. 6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea. Proc. Natl. Acad. Sci. USA, 93: 14088-14093, 1996.
32. 6-Benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow. Blood, 89: 1566-1573, 1997.
33. 6-alkylguanine-DNA alkyltransferase. Gene Ther., 5: 842-847, 1998.